ABBVIE INC. - ABBV STOCK NEWS

AbbVie announced robust financial results for Q4 2021, reporting worldwide net revenues of $14.886 billion, a 7.4% increase year-over-year. The immunology portfolio contributed $6.746 billion, while Humira's revenue reached $5.334 billion, showing a modest 3.5% rise. The company confirmed guidance of over $15 billion in combined sales for Skyrizi and Rinvoq by 2025. Notable FDA approvals for Rinvoq and Skyrizi expand treatment options, enhancing long-term growth prospects. Full-year 2022 EPS guidance is set between $9.26 and $9.46.

AbbVie (NYSE: ABBV) will showcase its IBD portfolio at the 17th Congress of ECCO from February 16-19, presenting 26 abstracts, including 8 oral and 10 poster presentations. These will focus on HUMIRA® and investigational treatments like risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®). Key analyses include the efficacy of risankizumab in Crohn's disease and the rapid symptom relief of ulcerative colitis with upadacitinib. AbbVie emphasizes its commitment to improve care for IBD patients through ongoing research and development.

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced an open casting call for individuals to share their personal BOTOX^® Cosmetic stories. This initiative supports their ongoing 'See Yourself' campaign aimed at fostering an authentic dialogue regarding aesthetic treatments. The casting call is open until March 2022, with a goal to reach even more consumers than the nearly one billion reached in 2021. Finalists will participate in a nationwide advertising campaign across various digital platforms.

AbbVie announced the FDA approval of SKYRIZI (risankizumab-rzaa) for treating adults with active psoriatic arthritis (PsA). This approval follows data from pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, showing significant efficacy compared to placebo in joint pain and other symptoms. SKYRIZI features a convenient dosing regimen of one injection every three months after initial doses. It aims to alleviate both skin and joint symptoms, improving quality of life for approximately 30% of psoriasis patients who experience PsA.

AbbVie announced that the FDA approved RINVOQ® (upadacitinib) for treating moderate to severe atopic dermatitis in adults and children aged 12 and older. This approval is significant for patients unresponsive to previous treatments, providing a once-daily oral option. Supported by data from over 2,500 patients in Phase 3 trials, RINVOQ demonstrated strong efficacy, with up to 80% of patients achieving significant skin clearance. However, it carries risks of serious infections and cardiovascular issues. AbbVie aims to improve patient access through support programs.

AbbVie confirms its revenue guidance for 2025, projecting combined risk-adjusted sales exceeding $15 billion from Rinvoq and Skyrizi. The forecast includes more than $7.5 billion in sales for each product. Adjustments were made due to lower sales expectations for Rinvoq in the U.S. after label updates, balanced by increased international sales and higher demand in Crohn's disease and ulcerative colitis, following positive Phase 3 study results. Skyrizi's growth is attributed to strong performance in psoriasis.

On January 11, 2022, ACELYRIN, INC. appointed Melanie Gloria as the new Chief Operating Officer (COO). With over 20 years in biotechnology, Gloria previously held senior roles at Abbott, AbbVie, and Horizon Therapeutics, leading R&D functions and achieving global therapy approvals. Her extensive background in drug development includes multiple therapeutic areas such as oncology and immunology. The leadership team believes Gloria's experience will enhance ACELYRIN's pursuit of life-changing treatments and support its growth strategy.

AbbVie has submitted applications for upadacitinib (RINVOQ^®) to the FDA and EMA to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who inadequately respond to NSAIDs. Based on the Phase 3 SELECT-AXIS 2 trial, upadacitinib showed efficacy in reducing symptoms and improving physical function. Additionally, AbbVie requested label enhancements for upadacitinib in the EU for active ankylosing spondylitis (AS). The safety profile remained consistent with previously known data, with no new risks identified.

AbbVie (NYSE: ABBV) is set to report its fourth-quarter and full-year 2021 financial results on February 2, 2022, before market opening. A live webcast of the earnings call will occur at 8 a.m. CT on the same day, accessible via AbbVie's Investor Relations website. Following the event, an archived version will be available for later viewing. AbbVie focuses on delivering innovative medicines across various therapeutic areas including immunology, oncology, and neuroscience.